Kapitalo Investimentos Ltda Acquires Shares of 523 Eli Lilly and Company (NYSE:LLY)

Kapitalo Investimentos Ltda bought a new position in shares of Eli Lilly and Company (NYSE:LLYFree Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 523 shares of the company’s stock, valued at approximately $305,000.

Other hedge funds also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $5,992,890,000. International Assets Investment Management LLC boosted its stake in shares of Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Sapient Capital LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $682,139,000. Vanguard Group Inc. increased its position in Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Finally, Comerica Bank bought a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $345,781,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $4.29 on Tuesday, reaching $889.30. 467,839 shares of the company’s stock traded hands, compared to its average volume of 2,924,406. The stock’s 50 day simple moving average is $788.10 and its two-hundred day simple moving average is $721.39. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $892.20. The stock has a market cap of $845.20 billion, a PE ratio of 130.34, a PEG ratio of 1.92 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.62 earnings per share. On average, analysts forecast that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a dividend of $1.30 per share. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 15,022 shares of Eli Lilly and Company stock in a transaction on Friday, June 14th. The stock was sold at an average price of $882.47, for a total value of $13,256,464.34. Following the completion of the transaction, the insider now directly owns 97,778,788 shares in the company, valued at $86,286,847,046.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 15,022 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $882.47, for a total transaction of $13,256,464.34. Following the sale, the insider now directly owns 97,778,788 shares in the company, valued at $86,286,847,046.36. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 567,826 shares of company stock worth $475,376,178 over the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LLY. BMO Capital Markets increased their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Truist Financial boosted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Bank of America raised their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Citigroup increased their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $787.53.

Read Our Latest Report on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.